Skip to main content
SpringerLink
Log in

Prevention of Breast Cancer

  • Chapter
Breast Cancer and Molecular Medicine

  • 1023 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albain K, Elledge R, Gradishar W et al (2002) Open label, phase II, multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat 76(suppl 1):S33 (abstract 20)

    Google Scholar 

  2. Alvarez RD, Conner MG, Weiss H et al (2003) The efficacy of 9-cis-retinoic acid (alitretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized doubleblind clinical trial. Cancer Epidemiol Biomarkers Prev 12:114–119

    PubMed  CAS  Google Scholar 

  3. Aranda A, Pascual A (2001) Nuclear hormone receptors and gene expression. Physiol Rev 81:1269–1304

    PubMed  CAS  Google Scholar 

  4. Baasch M, Nielsen SF, Engholm G et al (1996) Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer 73:961–963

    PubMed  CAS  Google Scholar 

  5. Barrett-Connor E, Grady D, Sashegyi A et al (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847–857

    PubMed  CAS  Google Scholar 

  6. Bernstein L (2002) Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 7:3–15

    PubMed  Google Scholar 

  7. Bernstein L, Deapen D, Cerhan JR et al (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654–1662

    PubMed  CAS  Google Scholar 

  8. Boice JD Jr, Persson I, Brinton LA et al (2000) Breast cancer following breast reduction surgery in Sweden. Plast Reconstr Surg 106:755–762

    PubMed  Google Scholar 

  9. Bray F, Sankila R, Ferlay J et al (2002) Estimates of cancer and mortality in Europe in 1995. Eur J Cancer 38:99–166

    PubMed  CAS  Google Scholar 

  10. Buzdar AU, Marcus C, Holmes F et al (1988) Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 45:344–345

    Article  PubMed  CAS  Google Scholar 

  11. Cauley JA, Norton L, Lippman ME et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134

    PubMed  CAS  Google Scholar 

  12. Chan KC, Knox F, Gee JM et al (2002) Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 62:122–128

    PubMed  CAS  Google Scholar 

  13. Conley B, O’Shaughnessy J, Prindiville S et al (2000) Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 18:275–283

    PubMed  CAS  Google Scholar 

  14. Costantino JP, Gail MH, Pee D et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548

    PubMed  CAS  Google Scholar 

  15. Cotterchio M, Kreiger N, Theis B et al (2003) Hormonal factors and the risk of breast cancer according to estrogen-and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev 12:1053–1060

    PubMed  CAS  Google Scholar 

  16. Cummings SR, Duong T, Kenyon E et al (2002) Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216–220

    PubMed  CAS  Google Scholar 

  17. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281:2189–2197

    PubMed  CAS  Google Scholar 

  18. Cuzick J, Baum M (1985) Tamoxifen and contralateral breast cancer. Lancet 2(8449):282

    PubMed  CAS  Google Scholar 

  19. Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 360:817–824

    PubMed  CAS  Google Scholar 

  20. Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300

    PubMed  CAS  Google Scholar 

  21. Day R, Ganz PA, Costantino JP et al (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol 17:2659–2669

    PubMed  CAS  Google Scholar 

  22. Day R, Ganz PA, Costantino JP (2001) Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project’s Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 93:1615–1623

    PubMed  CAS  Google Scholar 

  23. Decensi A, Bonanni B, Guerrieri-Gonzaga A et al (1998) Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90:1461–1467

    PubMed  CAS  Google Scholar 

  24. de Lima GR, Facina G, Shida JY et al (2003) Effect of low dose tamoxifen on normal breast tissue of premenopausal women. Eur J Cancer 39:891–898

    PubMed  Google Scholar 

  25. Delmas PD, Bjarnason NH, Mitlak BM et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647

    PubMed  CAS  Google Scholar 

  26. Dooley WC, Ljung BM, Veronesi U et al (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93:1624–1632

    PubMed  CAS  Google Scholar 

  27. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151

    PubMed  CAS  Google Scholar 

  28. Duvic M, Hymes K, Heald P et al (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19:2456–2471

    PubMed  CAS  Google Scholar 

  29. Early Breast Cancer Trialists Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

    Google Scholar 

  30. Eisinger F, Julian-Reynier C, Sobel H et al (2000) Acceptability of prophylactic mastectomy in cancer-prone women. JAMA 283:202–203

    PubMed  CAS  Google Scholar 

  31. Eisinger F, Julian-Reynier C, Stoppa-Lyonnet D et al (1998) Breast and ovarian cancer prone women and prophylactic surgery temptation. J Clin Oncol 16:2573–2575

    PubMed  CAS  Google Scholar 

  32. Ettinger B, Block DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645

    PubMed  CAS  Google Scholar 

  33. Fabian CJ, Kimler BF, Zalles CM, et al (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92:1217–1227

    PubMed  CAS  Google Scholar 

  34. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

    PubMed  CAS  Google Scholar 

  35. Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA mutation carriers. Lancet 343:692–695

    PubMed  CAS  Google Scholar 

  36. Formelli F, Clerici M, Campa T et al (1993) Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11:2036–2042

    PubMed  CAS  Google Scholar 

  37. Freedman AN, Graubard BI, Rao SR et al (2003) Estimates of the number of US women who could benefit from tamoxifen for breast cancer prevention. J Natl Cancer Inst 95:526–532

    PubMed  CAS  Google Scholar 

  38. Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886

    PubMed  CAS  Google Scholar 

  39. Gail MH, Costantino JP, Bryant J et al (1999) Weighing the risks and benefits of tamoxifen for treatment for preventing breast cancer. J Natl Cancer Inst 91:1829–1846

    PubMed  CAS  Google Scholar 

  40. Ganz PA, Day R, Ware JE et al (1995) Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 87:1372–1382

    PubMed  CAS  Google Scholar 

  41. Garber JE, Costantino JP, Wickerham DL et al (2002) Factor V Leiden and prothrombin G20210A mutations and risk of thromboembolic events in NSABP-P1, the Breast Cancer Prevention Trial. Breast Cancer Res Treat 76(suppl 1): S107 (abstract 413)

    Google Scholar 

  42. Geller G, Bernhardt BA, Doksum T et al (1998) Decision-making about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and atrisk women? J Clin Oncol 16:2868–2876

    PubMed  CAS  Google Scholar 

  43. Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316

    PubMed  CAS  Google Scholar 

  44. Goldstein SR (2000) Update on raloxifene to prevent endometrial-breast cancer. Eur J Cancer 36:S49–S56

    Google Scholar 

  45. Goss PE (2003) Breast cancer prevention—clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 86:487–493

    PubMed  CAS  Google Scholar 

  46. Gottardis MM, Jordan VC (1987) Antitumor actions of keoxifene and tamoxifen in the Nnitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020–4024

    PubMed  CAS  Google Scholar 

  47. Gradishar WJ, Glusman JE, Vogel CL et al (1997) Raloxifene HCL, a new endocrine agent is active in estrogen receptor positive metastatic breast cancer. Breast Cancer Res Treat 46:53 (abstract 209)

    Google Scholar 

  48. Grann VR, Panageas KS, Whang W et al (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16:979–985

    PubMed  CAS  Google Scholar 

  49. Green JE, Shibata MA, Yoshidone MK et al (2000) The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer. Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19:1020–1027

    PubMed  CAS  Google Scholar 

  50. Harris RE, Alshafie GA, Abou-Issa H et al (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60:2101–2103

    PubMed  CAS  Google Scholar 

  51. Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 14:71–84

    Google Scholar 

  52. Hartmann LC, Sellers TA, Schaid DJ et al (1999) Clinical options for women at high risk for breast cancer. Surg Clin North Am 79:1189–1206

    PubMed  CAS  Google Scholar 

  53. Hartmann LC, Sellers TA, Schaid DJ, et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633–1637

    PubMed  CAS  Google Scholar 

  54. Henderson BE, Ross R, Bernstein L (1988) Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 48:246–253

    PubMed  CAS  Google Scholar 

  55. Herschman HR. (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299:125–140

    PubMed  Google Scholar 

  56. Hildreth N, Shore R, Dvukresteski P et al (1989) The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 321:1281–1284

    PubMed  CAS  Google Scholar 

  57. Hoogerbrugge N, Bult P, de Widt-Leveret et al (2003) High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21:41–45

    PubMed  CAS  Google Scholar 

  58. Houn F, Helzlsouer KJ, Friedman NB, et al (1995) The practice of prophylactic mastectomy: a survey of Maryland surgeons. Am J Public Health 85:801–805

    PubMed  CAS  Google Scholar 

  59. Howe LR, Subbaramaiah K, Brown AMC et al (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8:97–114

    PubMed  CAS  Google Scholar 

  60. Howe LR, Subbaramaiah K, Patel J et al (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2/neu-induced breast cancer. Cancer Res 62:5405–5407

    PubMed  CAS  Google Scholar 

  61. Huang WY, Newman B, Millikan RC et al (2000) Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151:703–714

    PubMed  CAS  Google Scholar 

  62. Hugh Davies L et al (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115:523–525

    Google Scholar 

  63. Hwang D, Scollard D, Byrne J et al (1998) Expression of cyclooxygenase 1 and cyclooxygenase 2 in human breast cancer. J Natl Cancer Inst 90:455–460

    PubMed  CAS  Google Scholar 

  64. Inoue A, Saijo Y, Maemondo M et al (2003) Severe acute interstitial pneumonia and gefi-tinib. Lancet 361:137–139

    PubMed  Google Scholar 

  65. Jatoi I, Miller AB (2003) Why is breast-cancer mortality declining? Lancet Oncol 4:251–254

    PubMed  Google Scholar 

  66. Jemal A, Murray T, Samuels A et al (2003) Cancer statistics. 2003. CA Cancer J Clin 53:5–26

    PubMed  Google Scholar 

  67. Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9:1980–1989

    PubMed  CAS  Google Scholar 

  68. Johnston CC Jr, Bjarnason NH, Cohen FJ et al (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444–3450

    PubMed  CAS  Google Scholar 

  69. Jordan VC, Allen KE (1980) Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239–251

    PubMed  CAS  Google Scholar 

  70. Jordan VC, Allen KE, Dix CJ (1980) Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64:745–759

    PubMed  CAS  Google Scholar 

  71. Jordan VC, Labadidi MK, Langen-Fahey S (1991) Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83:492–496

    PubMed  CAS  Google Scholar 

  72. Jordan VC, Labadidi MK, Mirecki DM (1990) Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur J Cancer 26:718–721

    Article  PubMed  CAS  Google Scholar 

  73. Jordan VC, Morrow M (1999) Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20:253–278

    PubMed  CAS  Google Scholar 

  74. Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615

    PubMed  Google Scholar 

  75. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84:1188–1192

    PubMed  CAS  Google Scholar 

  76. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitInib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 290:2149–2158

    PubMed  CAS  Google Scholar 

  77. Kutchera W, Jones DA, Matsunami N et al (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A 93:4816–4820

    PubMed  CAS  Google Scholar 

  78. Lacassagne A (1936) Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 27:713–725

    Google Scholar 

  79. Lathrop AE, Loeb L (1916) Further investigations on the origins of tumors in mice III on the part played by internal secretions in the spontaneous development of tumors. J Cancer Res 1:1–16

    PubMed  CAS  Google Scholar 

  80. Lawrence JA, Adamson PC, Caruso R et al (2001) Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetics, and biomarker evaluations. J Clin Oncol 19:2754–2763

    PubMed  CAS  Google Scholar 

  81. Lerman C, Narod S, Schulman K et al (1996) BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 275:1885–1892

    PubMed  CAS  Google Scholar 

  82. Lerner LJ, Jordan VC (1990) Development of antiestrogens and their use in breast cancer. BF Cain Memorial Lecture. Cancer Res 50:4177–4189

    PubMed  CAS  Google Scholar 

  83. Li CI, Malone KE, Porter PL et al (2003) The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65–79 years of age. Cancer Epidemiol Biomarkers Prev 12:1061–1066

    PubMed  CAS  Google Scholar 

  84. Lippman ME, Krueger KA, Eckert S et al (2001) Indicators of lifetime estrogen exposure: effect of breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 19:3111–3116

    PubMed  CAS  Google Scholar 

  85. Liu CH, Chang SH, Narko K et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563–18569

    PubMed  CAS  Google Scholar 

  86. Lu C, Speers C, Zhang Y et al (2003) Effect of epidermal growth factor receptor inhibitor on development of estrogen-receptor negative mammary tumors. J Natl Cancer Inst 95:1825–1833

    PubMed  CAS  Google Scholar 

  87. Mann M, Sheng H, Shao J et al (2001) Targeting cyclooxygenase 2 and HER-2/neu pathway inhibits colorectal carcinoma growth. Gastroenterology 120:1713–1739

    PubMed  CAS  Google Scholar 

  88. Matloff ET, Shappell H, Brierley K et al (2000) What would you do? Specialists’ perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 18:2484–2492

    PubMed  CAS  Google Scholar 

  89. Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–64

    PubMed  CAS  Google Scholar 

  90. Meijers-Heijboer EJ, Verhog LC, Brekelmans CT et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA 1 or BRCA 2 mutation. Lancet 355:2015–2020

    PubMed  CAS  Google Scholar 

  91. Meiser B, Butow P, Friedlander M et al (2000) Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing breast cancer. J Clin Oncol 18:2250–2257

    PubMed  CAS  Google Scholar 

  92. Menard S, Camerini T, Mariani L et al (2001) Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 93:240–241

    PubMed  CAS  Google Scholar 

  93. Mettlin C (1999) Global breast cancer mortality statistics. CA Cancer J Clin 49:138–144

    PubMed  CAS  Google Scholar 

  94. Miller AB, How G, Sherman G et al (1989) Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 321:1285–1289

    PubMed  CAS  Google Scholar 

  95. Miller VA, Rigas JR, Benedetti FM et al (1996) Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res 2:471–475

    PubMed  CAS  Google Scholar 

  96. Moasser MM, Basso A, Averbuch SD et al (2001) The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184–7188

    PubMed  CAS  Google Scholar 

  97. Moon RC, Kelloff GJ, Detrisiac CJ et al (1992) Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res 12:1147–1153

    PubMed  CAS  Google Scholar 

  98. Moon RC, Thompson HJ, Becci PJ et al (1979) N-4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 39:1339–1346

    PubMed  CAS  Google Scholar 

  99. Morrow M (1992) Pre-cancerous breast lesions: implications for breast cancer prevention trials. Int J Radiat Oncol Biol Phys 23:1071–1078

    PubMed  CAS  Google Scholar 

  100. Morrow M, Bucci C, Rademaker A (1998) Medical contraindications are not a major factor in the underutilization of breast-conserving therapy. J Am Coll Surg 186:269–274

    PubMed  CAS  Google Scholar 

  101. Moscatello DK, Holgado-Madruga M, Godwin AK et al (1995) Frequent expression of a mutant epidermal growth factor receptor on multiple human tumors. Cancer Res 55:5536–5539

    PubMed  CAS  Google Scholar 

  102. Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 356:1876–1881

    PubMed  CAS  Google Scholar 

  103. Park JY, Su YQ, Ariga M et al (2004) EGF-like growth factors as mediators of LH action in the ovulatory follicle. Science 30:682–684

    Google Scholar 

  104. Parrett ML, Harris RE, Joarder FS et al (1997) Cyclooxygenase-2 expression in human breast cancer. Int J Oncol 10:503–507

    CAS  Google Scholar 

  105. Pennisi VR, Capozzi A (1989) Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 13:15–21

    PubMed  CAS  Google Scholar 

  106. Port ER, Montgomery LL, Heerdt AS et al (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8:580–585

    PubMed  CAS  Google Scholar 

  107. Powles TJ, Eeles R, Ashley SE et al (1998) Interim analysis of the incidence breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 362:98–101

    Google Scholar 

  108. Powles TJ, Hardy JR, Ashley SE et al (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126–131

    PubMed  CAS  Google Scholar 

  109. Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in mutation carriers. J Natl Cancer Inst 91:1475–1479

    PubMed  CAS  Google Scholar 

  110. Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622

    PubMed  Google Scholar 

  111. Reis SE, Costantino JP, Wickerham DL et al (2001) Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Cancer Prevention Trial Investigators. J Natl Cancer Inst 93:16–21

    PubMed  CAS  Google Scholar 

  112. Ristimaki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase 2 expression in breast cancer. Cancer Res 62:632–635

    PubMed  CAS  Google Scholar 

  113. Rizvi NA, Marshall JL, Dahut W et al (1999) A phase I study of LDG1069 in adults with advanced cancer. Clin Cancer Res 5:1658–1664

    PubMed  CAS  Google Scholar 

  114. Robertson JFR, Gutteridge E, Cheung KL, et al (2002) A phase II study of ZD1839 (Iressa) in tamoxifen resistant ER positive and endocrine insensitive (ER negative) breast cancer. Breast Cancer Res Treat 76(suppl 1):S96 (abstract 357)

    Google Scholar 

  115. Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3:49–61

    PubMed  CAS  Google Scholar 

  116. Saloman DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Google Scholar 

  117. Simon LS, Weaver AL, Graham DY et al (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282:1921–1928

    PubMed  CAS  Google Scholar 

  118. Soslow RA, Dannenberg AJ, Rush D et al (2000) Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637–245

    PubMed  CAS  Google Scholar 

  119. Sporn MB, Newton DL (1979) Chemoprevention of cancer with retinoids. Fed Proc 38:2528–2534

    PubMed  CAS  Google Scholar 

  120. Stefanek M, Enger C, Benkendorf J et al (1999) Bilateral prophylactic mastectomy decision making: a vignette study. Prev Med 29:216–221

    PubMed  CAS  Google Scholar 

  121. Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952

    PubMed  CAS  Google Scholar 

  122. Subbaramaiah K, Norton L, Gerald W et al (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649–18657

    PubMed  CAS  Google Scholar 

  123. Tan-Chiu E, Wang J, Costantino JP et al (2003) Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 95:302–307

    PubMed  CAS  Google Scholar 

  124. Tchou J, Hou N, Rademaker A et al (2004) Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 103:209–210

    Google Scholar 

  125. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139

    Google Scholar 

  126. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC trial efficacy and safety update analysis. Cancer 98:1002–1010

    Google Scholar 

  127. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:973–976

    Google Scholar 

  128. Tokanaga M, Land CE, Yamamoto T et al (1987) Incidence of female breast cancer among atomic bomb survivors: Hiroshima and Nagasaki 1950–1980. Radiat Res 112:243–272

    Google Scholar 

  129. Torrance CJ, Jackson PE, Montgomery E et al (2000) Combinatorial chemoprevention of intestinal neoplasia. Nature Med 8:1024–1028

    Google Scholar 

  130. Torrisi R, Pensa F, Orengo MA et al (1993) The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 53:4769–4771

    PubMed  CAS  Google Scholar 

  131. Trichopoulos D, MacMahon B, Cole P (1972) Menopause and breast cancer risk. J Natl Cancer Inst 48:605–613

    PubMed  CAS  Google Scholar 

  132. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212

    PubMed  CAS  Google Scholar 

  133. Veronesi U, De Palo G, Marubini E et al (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91:1847–1856

    PubMed  CAS  Google Scholar 

  134. Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352:93–97

    PubMed  CAS  Google Scholar 

  135. Veronesi U, Maisonneuve P, Rotmensz N et al (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–165

    PubMed  CAS  Google Scholar 

  136. Veronesi U, Maisonneuve P, Sacchini V et al (2002) Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122–1124

    PubMed  CAS  Google Scholar 

  137. Vogel VG, Costantino JP, Wickerham DL et al (2002) The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer reduction trial. Clin Breast Cancer 3:153–159

    Article  PubMed  Google Scholar 

  138. Voldborg BR, Damstrup L, Spang-Thomsen M et al (1997) EGFR and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197–1206

    PubMed  CAS  Google Scholar 

  139. Wagner TM, Mösingler R, Langbauer G et al (2000) Attitude towards prophylactic surgery and effects of genetic counseling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 82:1249–1253

    PubMed  CAS  Google Scholar 

  140. Warner E, Plewes DB, Shumak RS, et al (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524–3531

    PubMed  CAS  Google Scholar 

  141. Wenger NK, Barrett-Connor E, Collins P et al (2002) Baseline characteristics of participants in the Raloxifene Use for the Heart (RUTH) trial. Am J Cardiol 90:1204–1210

    PubMed  CAS  Google Scholar 

  142. Wickerham DL, Fisher B, Wolmark N et al (2002) Association of tamoxifen and uterine sarcoma. J Clin Oncol 20:2758–2760

    PubMed  Google Scholar 

  143. Winer E, Cobleigh M, Dickler M et al (2002) Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotnib; OSI-774) in women with previous treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 76(suppl 1): (abstract 445)

    Google Scholar 

  144. Wu K, Kim HT, Rodriquez JL et al (2000) 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res 6:3696–3704

    PubMed  CAS  Google Scholar 

  145. Wu K, Kim HT, Rodriquez JL et al (2002) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11:467–474

    PubMed  CAS  Google Scholar 

  146. Ziegler LD, Kroll SS (1991) Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 14:451–454

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Fox Chase Cancer Center Department of Surgery, 333 Cotman Ave, Philadelphia, PA, 19111-2497, USA

    Monica Morrow (Chairman)

  2. Department of Surgery, Fox Chase Cancer Center, 333 Cotman Ave, Philadelphia, PA, 19111-2497, USA

    V. Craig Jordan

Authors
  1. Monica Morrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 215, 1000, Brussels, Belgium

    Martine J. Piccart MD, PhD  & Fatima Cardoso MD  & 

  2. Anderson Cancer Center, The University of Texas MD, 1515 Holcombe Blvd, Houston, TX, 77030-4095, USA

    Mien-Chie Hung PhD

  3. Dept. of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104-4283, USA

    Lawrence J. Solin MD

  4. Dept. of Surgery, Emory University Hospital, 1364 Clifton Road NE B206, Atlanta, Georgia, 30322-1059, USA

    William C. Wood MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Morrow, M., Jordan, V.C. (2006). Prevention of Breast Cancer. In: Piccart, M.J., Hung, MC., Solin, L.J., Cardoso, F., Wood, W.C. (eds) Breast Cancer and Molecular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28266-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28266-2_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28265-5

  • Online ISBN: 978-3-540-28266-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation